217 related articles for article (PubMed ID: 19125120)
1. Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM
Cancer Nurs; 2009; 32(2):143-50. PubMed ID: 19125120
[TBL] [Abstract][Full Text] [Related]
2. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Singh S; Cuzick J; Mesher D; Richmond B; Howell A
Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
[TBL] [Abstract][Full Text] [Related]
3. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
[TBL] [Abstract][Full Text] [Related]
4. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
5. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
6. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
[TBL] [Abstract][Full Text] [Related]
8. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
[TBL] [Abstract][Full Text] [Related]
11. The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.
Peppone LJ; Janelsins MC; Kamen C; Mohile SG; Sprod LK; Gewandter JS; Kirshner JJ; Gaur R; Ruzich J; Esparaz BT; Mustian KM
Breast Cancer Res Treat; 2015 Apr; 150(3):597-604. PubMed ID: 25814054
[TBL] [Abstract][Full Text] [Related]
12. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Kemp A; Preen DB; Saunders C; Boyle F; Bulsara M; Holman CD; Malacova E; Roughead EE
PLoS One; 2014; 9(1):e84835. PubMed ID: 24392158
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Winters L; Habin K; Gallagher J
Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
[TBL] [Abstract][Full Text] [Related]
15. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
Napoli N; Vattikuti S; Ma C; Rastelli A; Rayani A; Donepudi R; Asadfard M; Yarramaneni J; Ellis M; Armamento-Villareal R
Breast J; 2010; 16(6):609-16. PubMed ID: 21070438
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Morales L; Neven P; Timmerman D; Christiaens MR; Vergote I; Van Limbergen E; Carbonez A; Van Huffel S; Ameye L; Paridaens R
Anticancer Drugs; 2004 Sep; 15(8):753-60. PubMed ID: 15494636
[TBL] [Abstract][Full Text] [Related]
18. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Morales L; Pans S; Paridaens R; Westhovens R; Timmerman D; Verhaeghe J; Wildiers H; Leunen K; Amant F; Berteloot P; Smeets A; Van Limbergen E; Weltens C; Van den Bogaert W; De Smet L; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2007 Jul; 104(1):87-91. PubMed ID: 17061044
[TBL] [Abstract][Full Text] [Related]
19. Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on depression, anxiety, functional capacity and health-related quality of Life in breast cancer survivors during adjuvant endocrine therapy.
Custódio IDD; Nunes FSM; Lima MTM; de Carvalho KP; Alves DS; Chiaretto JF; Canto PPL; Paiva CE; de Paiva Maia YC
BMC Cancer; 2022 Aug; 22(1):860. PubMed ID: 35933326
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]